Skip to main content
OpenTrials
Completed

NCT Number: NCT01628289

The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong

Introduction: There is no debate that people with diabetes should be screened for the development of retinopathy which can threaten their sight. However, there is no routine screening for retinopathy in Hong Kong at present. Many overseas countries find that they miss a large proportion of their target population and, with reliance on co-payments for screening, as is the case with the limited opportunistic screening at present, the cost-effectiveness of any routine service in Hong Kong could be reduced as is predicted by Hart's inverse care law.

Aim: This study will determine the potential cost-effectiveness of screening for retinopathy in Hong Kong under a free system and one in which a co-payment is charged.

Methods: Primary care patients attending General Outpatient Clinics on Hong Kong Island for their routine diabetic care will randomly be offered screening either at no charge or with the normal co-payment of $65. Those who are willing and unwilling to be screened will be compared for their clinical, lifestyle and socioeconomic characteristics and those unwilling will be asked their reasons. The uptake of screening at no fee and with a payment will be compared as will the prevalence of retinopathy in the two fee groups. Subsequent screening at one year will be offered at the same fee and uptake again compared.

The principal analyses will (a) identify the characteristics of those willing to be screened and reasons for not being screened (b) the uptake of screening when a co-payment is charged compared to when it is free (c) whether there is a difference in the prevalence of retinopathy between the group willing to pay and those who accept free screening and (d) the uptake of re-screening in year 2.

The resulting cost-effectiveness model will use these data, the cost data collected during the study and overseas data on benefits of treatment to model the cost-effectiveness of screening for retinopathy in Hong Kong if it were to be offered free or with a co-payment. This information will be important to determine the most cost-effective means of implementing this preventative strategy to preserve sight and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aberdeen General Outpatient Clinic,Hospital Authority, Hong Kong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All diabetic patients who attend the clinic during the study period.

Exclusion criteria

  • Only if not competent to give informed consent

Treatment and study plan

charging a co-payment for Diabetic Retinopathy screening

Other

The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.

free screening without charging a co-payment

Other

The intervention is to provide free screening without charging a co-payment

Primary outcomes

  1. Retinopathy profile in the two groups

    Time frame: the first year

    The extent of diabetic retinopathy in two groups were measured in the first year screening.

Secondary outcomes

  1. Subjects' attendance of the screening

    Time frame: the first year

    Whether the subject attends the screening was measured and the attendance rate was estimated for two groups in the first year screening.

  2. Retinopathy profile in the two groups

    Time frame: the second year

    The extent of diabetic retinopathy in two groups were measured in the second year screening.

  3. Subjects' attendance of the screening

    Time frame: the second year

    Whether the subject attends the screening was measured and the attendance rate was estimated for two groups in the second year screening.

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
Jun 26, 2012
Registry last updated
Jun 26, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.